CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands |
12 Months Ended |
Dec. 31, 2021 |
Dec. 31, 2020 |
| Cash flow from operating activities |
|
|
| Net loss |
$ (10,440)
|
$ (10,882)
|
| Adjustments to reconcile net loss to net cash used in operating activities |
|
|
| Stock-based compensation |
821
|
577
|
| Amortization of right of use assets |
85
|
79
|
| Depreciation |
76
|
72
|
| (Increase) decrease in operating assets |
|
|
| Prepaid drug product |
750
|
(497)
|
| Other current assets |
(915)
|
(140)
|
| Increase (decrease) in operating liabilities |
|
|
| Accounts payable and accrued expenses |
(199)
|
(84)
|
| Lease liabilities |
(95)
|
(85)
|
| Net cash used in operating activities |
(9,917)
|
(10,960)
|
| Cash flow from investing activities |
|
|
| Purchases of furniture, fixtures & equipment |
(70)
|
|
| Net cash used in investing activities |
(70)
|
|
| Cash flow from financing activities |
|
|
| Net proceeds from sale of common stock |
15,849
|
4,289
|
| Net proceeds from exercise of warrants |
4,157
|
|
| Net cash provided by financing activities |
20,006
|
4,289
|
| Net increase (decrease) in cash |
10,019
|
(6,671)
|
| Cash, beginning of period |
13,755
|
20,426
|
| Cash, end of period |
$ 23,774
|
$ 13,755
|